Shao Yu-Yun, Lin Zhong-Zhe, Liang Po-Chin, Tien Yu-Wen, Cheng Ann-Lii
Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Rd, Taipei 10002, Taiwan, R.O.C.
Anticancer Res. 2009 May;29(5):1665-7.
Bowel perforation is a rare but life-threatening complication of bevacizumab, a new anticancer treatment. Patients with bowel perforation usually present with acute abdominal symptoms. Here a case history is presented to highlight a pancreatic cancer patient on bevacizumab chemotherapy who developed empyema as the first manifestation of gastric perforation. This unusual presentation warns physicians that bevacizumab-related bowel perforation can arise as a thoracic complication, without typical gastrointestinal manifestations, in an advanced cancer patient.
肠穿孔是一种新型抗癌治疗药物贝伐单抗罕见但危及生命的并发症。肠穿孔患者通常表现为急性腹部症状。本文介绍了一例病史,以突出一名接受贝伐单抗化疗的胰腺癌患者,其以脓胸作为胃穿孔的首发表现。这种不寻常的表现提醒医生,在晚期癌症患者中,与贝伐单抗相关的肠穿孔可能作为一种胸部并发症出现,而无典型的胃肠道表现。